{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T03:01:59Z","timestamp":1740106919409,"version":"3.37.3"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2024,10,28]],"date-time":"2024-10-28T00:00:00Z","timestamp":1730073600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,10,28]],"date-time":"2024-10-28T00:00:00Z","timestamp":1730073600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Skeletal Radiol"],"DOI":"10.1007\/s00256-024-04810-4","type":"journal-article","created":{"date-parts":[[2024,10,28]],"date-time":"2024-10-28T09:29:07Z","timestamp":1730107747000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Multiple myeloma: What is the most cost-effective imaging strategy for initial detection of bone lesions?"],"prefix":"10.1007","author":[{"given":"Soterios","family":"Gyftopoulos","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arnau","family":"Hanly","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naveen","family":"Subhas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Noopur","family":"Raje","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1304-1576","authenticated-orcid":false,"given":"Connie Y.","family":"Chang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,10,28]]},"reference":[{"key":"4810_CR1","doi-asserted-by":"publisher","first-page":"e302","DOI":"10.1016\/S1470-2045(19)30309-2","volume":"20","author":"J Hillengass","year":"2019","unstructured":"Hillengass J, Usmani S, Rajkumar SV, Durie BGM, Mateos M-V, Lonial S, et al. International myeloma working group consensus recommendations on imaging in monoclonal plasma cell disorders. Lancet Oncol. 2019;20:e302\u201312.","journal-title":"Lancet Oncol."},{"key":"4810_CR2","doi-asserted-by":"publisher","first-page":"232","DOI":"10.3324\/haematol.2013.099358","volume":"99","author":"M Engelhardt","year":"2014","unstructured":"Engelhardt M, Terpos E, Kleber M, Gay F, W\u00e4sch R, Morgan G, et al. European Myeloma Network recommendations on the evaluation and treatment of newly diagnosed patients with multiple myeloma. Haematologica. 2014;99:232\u201342.","journal-title":"Haematologica."},{"key":"4810_CR3","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1182\/blood-2018-08-825356","volume":"133","author":"E Zamagni","year":"2019","unstructured":"Zamagni E, Tacchetti P, Cavo M. Imaging in multiple myeloma: How? When? Blood. 2019;133:644\u201351.","journal-title":"Blood."},{"key":"4810_CR4","doi-asserted-by":"crossref","unstructured":"Rosenthal DI. Floccinaucinihilipilification: is there a continuing role for the radiographic skeletal survey? Skeletal Radiol. 2021.","DOI":"10.1007\/s00256-021-03780-1"},{"key":"4810_CR5","doi-asserted-by":"publisher","first-page":"463","DOI":"10.2214\/AJR.22.28229","volume":"220","author":"S Ahlawat","year":"2023","unstructured":"Ahlawat S, Debs P, Amini B, Lecouvet FE, Omoumi P, Wessell DE. Clinical applications and controversies of whole-body MRI: AJR expert panel narrative review. AJR Am J Roentgenol. 2023;220:463\u201375.","journal-title":"AJR Am J Roentgenol."},{"key":"4810_CR6","unstructured":"U.S. Health Care from a Global Perspective, 2022: Accelerating Spending, Worsening Outcomes [Internet]. 2023 [cited 2023 Jul 8]. Available from: https:\/\/www.commonwealthfund.org\/publications\/issue-briefs\/2023\/jan\/us-health-care-global-perspective-2022."},{"key":"4810_CR7","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1182\/hematology.2022000347","volume":"2022","author":"TM Schmidt","year":"2022","unstructured":"Schmidt TM. High or low? Assessing disease risk in multiple myeloma. Hematol Am Soc Hematol Educ Program. 2022;2022:349\u201355.","journal-title":"Hematol Am Soc Hematol Educ Program."},{"key":"4810_CR8","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1056\/NEJMoa1709974","volume":"378","author":"RA Kyle","year":"2018","unstructured":"Kyle RA, Larson DR, Therneau TM, Dispenzieri A, Kumar S, Cerhan JR, et al. Long-term follow-up of monoclonal gammopathy of undetermined significance. N Engl J Med. 2018;378:241\u20139.","journal-title":"N Engl J Med."},{"key":"4810_CR9","doi-asserted-by":"publisher","first-page":"e538","DOI":"10.1016\/S1470-2045(14)70442-5","volume":"15","author":"SV Rajkumar","year":"2014","unstructured":"Rajkumar SV, Dimopoulos MA, Palumbo A, Blade J, Merlini G, Mateos M-V, et al. International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol. 2014;15:e538\u201348.","journal-title":"Lancet Oncol."},{"key":"4810_CR10","first-page":"831","volume":"23","author":"Y Chen","year":"2017","unstructured":"Chen Y, Lairson DR, Chan W, Huo J, Du XL. Cost-effectiveness of novel agents in Medicare patients with multiple Myeloma: findings from a U.S. payer\u2019s perspective. J Manag Care Spec Pharm. 2017;23:831\u201343.","journal-title":"J Manag Care Spec Pharm"},{"key":"4810_CR11","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1111\/bjh.17088","volume":"193","author":"E Hill","year":"2021","unstructured":"Hill E, Mena E, Morrison C, Dew A, Choyke P, Lindenberg L, et al. Diagnostic performance of 18 F-FDG-PET\/CT compared to standard skeletal survey for detecting bone destruction in smouldering multiple myeloma: time to move forward. Br J Haematol. 2021;193:125\u20138.","journal-title":"Br J Haematol."},{"key":"4810_CR12","first-page":"1077","volume":"39","author":"AG Ormond Filho","year":"2019","unstructured":"Ormond Filho AG, Carneiro BC, Pastore D, Silva IP, Yamashita SR, Consolo FD, et al. Whole-body imaging of multiple myeloma: diagnostic criteria. Radiogr Rev Publ Radiol Soc N Am Inc. 2019;39:1077\u201397.","journal-title":"Radiogr Rev Publ Radiol Soc N Am Inc"},{"key":"4810_CR13","doi-asserted-by":"publisher","first-page":"980","DOI":"10.2214\/AJR.08.1633","volume":"192","author":"CP Shortt","year":"2009","unstructured":"Shortt CP, Gleeson TG, Breen KA, McHugh J, O\u2019Connell MJ, O\u2019Gorman PJ, et al. Whole-body MRI versus PET in assessment of multiple myeloma disease activity. AJR Am J Roentgenol. 2009;192:980\u20136.","journal-title":"AJR Am J Roentgenol."},{"key":"4810_CR14","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1002\/jmri.22608","volume":"34","author":"L-M Wu","year":"2011","unstructured":"Wu L-M, Gu H-Y, Zheng J, Xu X, Lin L-H, Deng X, et al. Diagnostic value of whole-body magnetic resonance imaging for bone metastases: a systematic review and meta-analysis. J Magn Reson Imaging JMRI. 2011;34:128\u201335.","journal-title":"J Magn Reson Imaging JMRI."},{"key":"4810_CR15","doi-asserted-by":"publisher","first-page":"17272","DOI":"10.1038\/s41598-021-96804-8","volume":"11","author":"K Hemminki","year":"2021","unstructured":"Hemminki K, F\u00f6rsti A, Hansson M. Incidence, mortality and survival in multiple myeloma compared to other hematopoietic neoplasms in Sweden up to year 2016. Sci Rep. 2021;11:17272.","journal-title":"Sci Rep."},{"key":"4810_CR16","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1002\/cncr.23546","volume":"113","author":"B Barlogie","year":"2008","unstructured":"Barlogie B, Anaissie E, Haessler J, van Rhee F, Pineda-Roman M, Hollmig K, et al. Complete remission sustained 3 years from treatment initiation is a powerful surrogate for extended survival in multiple myeloma. Cancer. 2008;113:355\u20139.","journal-title":"Cancer."},{"key":"4810_CR17","doi-asserted-by":"publisher","first-page":"2208","DOI":"10.1038\/leu.2016.147","volume":"30","author":"N Majithia","year":"2016","unstructured":"Majithia N, Rajkumar SV, Lacy MQ, Buadi FK, Dispenzieri A, Gertz MA, et al. Early relapse following initial therapy for multiple myeloma predicts poor outcomes in the era of novel agents. Leukemia. 2016;30:2208\u201313.","journal-title":"Leukemia."},{"key":"4810_CR18","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1182\/blood-2013-05-505487","volume":"123","author":"I Turesson","year":"2014","unstructured":"Turesson I, Kovalchik SA, Pfeiffer RM, Kristinsson SY, Goldin LR, Drayson MT, et al. Monoclonal gammopathy of undetermined significance and risk of lymphoid and myeloid malignancies: 728 cases followed up to 30 years in Sweden. Blood. 2014;123:338\u201345.","journal-title":"Blood."},{"key":"4810_CR19","doi-asserted-by":"publisher","first-page":"1153","DOI":"10.1007\/s40273-020-00937-z","volume":"38","author":"R Gidwani","year":"2020","unstructured":"Gidwani R, Russell LB. Estimating transition probabilities from published evidence: a tutorial for decision modelers. PharmacoEconomics. 2020;38:1153\u201364.","journal-title":"PharmacoEconomics."},{"key":"4810_CR20","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1016\/j.jval.2020.04.1825","volume":"23","author":"D Golicki","year":"2020","unstructured":"Golicki D, Ja\u015bkowiak K, W\u00f3jcik A, M\u0142y\u0144czak K, Dobrowolska I, Gawro\u0144ska A, et al. EQ-5D\u2013derived health state utility values in hematologic malignancies: a catalog of 796 utilities based on a systematic review. Value Health. 2020;23:953\u201368.","journal-title":"Value Health."},{"key":"4810_CR21","first-page":"29","volume":"24","author":"JJ Carlson","year":"2018","unstructured":"Carlson JJ, Guzauskas GF, Chapman RH, Synnott PG, Liu S, Russo ET, et al. Cost-effectiveness of drugs to treat relapsed\/refractory multiple myeloma in the United States. J Manag Care Spec Pharm. 2018;24:29\u201338.","journal-title":"J Manag Care Spec Pharm."},{"key":"4810_CR22","volume-title":"Methods for the economic evaluation of health care programmes","author":"M Drummond","year":"2015","unstructured":"Drummond M, Sculpher M, Claxton K, Stoddard G, Torrance G. Methods for the economic evaluation of health care programmes. 4th ed. Oxford University Press; 2015.","edition":"4"},{"key":"4810_CR23","doi-asserted-by":"publisher","first-page":"2490","DOI":"10.3892\/ol.2017.5723","volume":"13","author":"L Lambert","year":"2017","unstructured":"Lambert L, Ourednicek P, Meckova Z, Gavelli G, Straub J, Spicka I. Whole-body low-dose computed tomography in multiple myeloma staging: Superior diagnostic performance in the detection of bone lesions, vertebral compression fractures, rib fractures and extraskeletal findings compared to radiography with similar radiation exposure. Oncol Lett. 2017;13:2490\u20134.","journal-title":"Oncol Lett."},{"key":"4810_CR24","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1038\/s41408-018-0124-1","volume":"8","author":"LA Moulopoulos","year":"2018","unstructured":"Moulopoulos LA, Koutoulidis V, Hillengass J, Zamagni E, Aquerreta JD, Roche CL, et al. Recommendations for acquisition, interpretation and reporting of whole body low dose CT in patients with multiple myeloma and other plasma cell disorders: a report of the IMWG Bone Working Group. Blood Cancer J. 2018;8:95.","journal-title":"Blood Cancer J."},{"key":"4810_CR25","doi-asserted-by":"publisher","first-page":"1622","DOI":"10.2214\/AJR.06.1403","volume":"188","author":"D-M Koh","year":"2007","unstructured":"Koh D-M, Collins DJ. Diffusion-weighted MRI in the body: applications and challenges in oncology. AJR Am J Roentgenol. 2007;188:1622\u201335.","journal-title":"AJR Am J Roentgenol."},{"key":"4810_CR26","doi-asserted-by":"publisher","unstructured":"Van Den Berghe T, Verstraete KL, Lecouvet FE, Lejoly M, Dutoit J. Review of diffusion-weighted imaging and dynamic contrast\u2013enhanced MRI for multiple myeloma and its precursors (monoclonal gammopathy of undetermined significance and smouldering myeloma). Skeletal Radiol [Internet]. 2021. Available from: https:\/\/doi.org\/10.1007\/s00256-021-03903-8","DOI":"10.1007\/s00256-021-03903-8"},{"key":"4810_CR27","doi-asserted-by":"publisher","first-page":"e415","DOI":"10.3324\/haematol.2016.146092","volume":"101","author":"M Hinge","year":"2016","unstructured":"Hinge M, Andersen KT, Lund T, J\u00f8rgensen HB, Holdgaard PC, Ormstrup TE, et al. Baseline bone involvement in multiple myeloma - a prospective comparison of conventional X-ray, low-dose computed tomography, and 18flourodeoxyglucose positron emission tomography in previously untreated patients. Haematologica. 2016;101:e415\u20138.","journal-title":"Haematologica."},{"key":"4810_CR28","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1007\/s00330-007-0738-3","volume":"18","author":"P Kr\u00f6pil","year":"2008","unstructured":"Kr\u00f6pil P, Fenk R, Fritz LB, Blondin D, Kobbe G, M\u00f6dder U, et al. Comparison of whole-body 64-slice multidetector computed tomography and conventional radiography in staging of multiple myeloma. Eur Radiol. 2008;18:51\u20138.","journal-title":"Eur Radiol."},{"key":"4810_CR29","doi-asserted-by":"publisher","first-page":"1222","DOI":"10.1016\/j.ejrad.2014.02.008","volume":"83","author":"MB Wolf","year":"2014","unstructured":"Wolf MB, Murray F, Kilk K, Hillengass J, Delorme S, Heiss C, et al. Sensitivity of whole-body CT and MRI versus projection radiography in the detection of osteolyses in patients with monoclonal plasma cell disease. Eur J Radiol. 2014;83:1222\u201330.","journal-title":"Eur J Radiol."},{"key":"4810_CR30","doi-asserted-by":"publisher","first-page":"50","DOI":"10.3324\/haematol.10554","volume":"92","author":"E Zamagni","year":"2007","unstructured":"Zamagni E, Nanni C, Patriarca F, Englaro E, Castellucci P, Geatti O, et al. A prospective comparison of 18F-fluorodeoxyglucose positron emission tomography-computed tomography, magnetic resonance imaging and whole-body planar radiographs in the assessment of bone disease in newly diagnosed multiple myeloma. Haematologica. 2007;92:50\u20135.","journal-title":"Haematologica."},{"key":"4810_CR31","first-page":"1331","volume":"64","author":"F Kraeber-Bod\u00e9r\u00e9","year":"2023","unstructured":"Kraeber-Bod\u00e9r\u00e9 F, Jamet B, Bezzi D, Zamagni E, Moreau P, Nanni C. New developments in myeloma treatment and response assessment. J Nucl Med Off Publ Soc Nucl Med. 2023;64:1331\u201343.","journal-title":"J Nucl Med Off Publ Soc Nucl Med."},{"key":"4810_CR32","doi-asserted-by":"crossref","unstructured":"Lecouvet FE, Vekemans M-C, Van Den Berghe T, Verstraete K, Kirchgesner T, Acid S, et al. Imaging of treatment response and minimal residual disease in multiple myeloma: state of the art WB-MRI and PET\/CT. Skeletal Radiol. 2021.","DOI":"10.1007\/s00256-021-03841-5"},{"key":"4810_CR33","doi-asserted-by":"publisher","first-page":"1885","DOI":"10.3390\/jpm12111885","volume":"12","author":"A Santoni","year":"2022","unstructured":"Santoni A, Simoncelli M, Franceschini M, Ciofini S, Fredducci S, Caroni F, et al. Functional imaging in the evaluation of treatment response in multiple myeloma: the Role of PET-CT and MRI. J Pers Med. 2022;12:1885.","journal-title":"J Pers Med."},{"key":"4810_CR34","doi-asserted-by":"publisher","first-page":"2546","DOI":"10.1080\/10428194.2018.1434881","volume":"59","author":"A Stecco","year":"2018","unstructured":"Stecco A, Buemi F, Iannessi A, Carriero A, Gallamini A. Current concepts in tumor imaging with whole-body MRI with diffusion imaging (WB-MRI-DWI) in multiple myeloma and lymphoma. Leuk Lymphoma. 2018;59:2546\u201356.","journal-title":"Leuk Lymphoma."},{"key":"4810_CR35","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1007\/s00256-018-3066-6","volume":"48","author":"FJ Simeone","year":"2019","unstructured":"Simeone FJ, Harvey JP, Yee AJ, O\u2019Donnell EK, Raje NS, Torriani M, et al. Value of low-dose whole-body CT in the management of patients with multiple myeloma and precursor states. Skeletal Radiol. 2019;48:773\u20139.","journal-title":"Skeletal Radiol."},{"key":"4810_CR36","doi-asserted-by":"publisher","first-page":"20140185","DOI":"10.1259\/bjr.20140185","volume":"87","author":"A Surov","year":"2014","unstructured":"Surov A, Bach AG, Tcherkes A, Schramm D. Non-osseous incidental findings in low-dose whole-body CT in patients with multiple myeloma. Br J Radiol. 2014;87:20140185.","journal-title":"Br J Radiol."}],"container-title":["Skeletal Radiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00256-024-04810-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00256-024-04810-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00256-024-04810-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,28]],"date-time":"2024-10-28T18:02:43Z","timestamp":1730138563000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00256-024-04810-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,28]]},"references-count":36,"alternative-id":["4810"],"URL":"https:\/\/doi.org\/10.1007\/s00256-024-04810-4","relation":{},"ISSN":["0364-2348","1432-2161"],"issn-type":[{"type":"print","value":"0364-2348"},{"type":"electronic","value":"1432-2161"}],"subject":[],"published":{"date-parts":[[2024,10,28]]},"assertion":[{"value":"9 July 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 September 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 September 2024","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 October 2024","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not required because there were no patients.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"None required because no patient data was used.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"The authors declare that they have no conflict of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}